Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes is organized by i3 Health and will be held from May 16, 2023 - May 15, 2024.
Statement of Need:
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al., 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies based on tumor location and stage, human papillomavirus (HPV) status, the need to preserve surrounding organs and tissues, and impacts on quality of life (NCCN, 2023). Remaining up to date on emerging treatment options and management strategies for HNSCC is vital. This activity led by Assuntina Sacco, MD, Associate Professor of Medicine at Moores Cancer Center of UC San Diego Health, will provide new insights and real-world guidance for improved outcomes in recurrent and metastatic HNSCC.
Upon completion of this activity, participants should be able to:
In this activity, discover new insights and real-world evidence for improved patient outcomes in recurrent/metastatic head and neck squamous cell carcinoma from Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine at the University of California, San Diego Health. Learn about differing therapeutic strategies based on tumor location and stage, human papillomavirus (HPV) status, the need to preserve surrounding organs and tissues, impacts on quality of life, and more.